Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Trial Evaluates FDA-Designated Breakthrough Therapy for Patients Who Lack Treatment Options

News | Heart Failure

Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population

November 22, 2022 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with ...

November 22, 2022

CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve technology for the treatment of Tricuspid Regurgitation as part of its TANDEM I study in Poland.

News | Heart Valve Technology

CroíValve Reports Successful First in Human Implants of its DUO Tricuspid Coaptation Valve System

November 22, 2022 — CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve ...

November 22, 2022

Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo)

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

UH Cleveland Medical Center. Image courtesy of University Hospitals

News | Deep Vein Thrombosis (DVT)

Four Prospective, Multicenter Studies Support Use of Drug-Coated Balloons Over Bare Metal Stents in Treating Femoropopliteal Lesions

November 21, 2022 — New research published in the Journal of the American College of Cardiology shows the use of drug ...

November 21, 2022

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide, according to the American Heart Association.

News | Heart Failure

Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology

November 21, 2022 — Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide ...

November 21, 2022

Justin Balko, PharmD, PhD, Ingram Associate Professor of Cancer Research, and a co-corresponding author of the study. Credit: Vanderbilt University Medical Center

News | Heart Failure

Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

November 22, 2022 — Myocarditis is a complication that can occur in cancer patients treated with immune checkpoint ...

November 21, 2022

Screen shots of Viz PE with RV/LV ratio data (left), along with the company’s ECG Viewer (right). Both are part of the comprehensive Viz Cardio Suite designed to speed and improve patient access to innovative cardiovascular treatments. Source: Viz.ai.

News | Pulmonary Embolism

Viz.ai Launches AI-Powered Viz Cardio Suite

November 17, 2022 — Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, announced the ...

November 17, 2022

Certain adults with this artery-blocking condition may see more benefits with an open bypass compared to less-invasive procedures to improve circulation.

News | Peripheral Artery Disease (PAD)

Bypass Surgery Favorable for Initial Treatment of Chronic Limb-Threatening Ischemia

November 15, 2022 Performing open bypass surgery to restore circulation for people with a severe form of peripheral ...

November 15, 2022

UMSOM researchers display first genetically modified pig heart transplanted into living patient. Image courtesy of University of Maryland School of Medicine

News | Heart Failure

Unexpected Electrical Changes Seen in First Successful Transplant of Genetically-Modified Pig Heart

November 15, 2022 — Ten months after transplanting the first genetically-modified pig heart into a human patient ...

November 15, 2022

When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies.

News | Heart Failure

Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women

November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

November 14, 2022

Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System

News | Antiplatelet and Anticoagulation Therapies

Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

November 14, 2022

The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.

News | AHA

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

November 14, 2022

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

News | Heart Failure

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 9, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

November 09, 2022

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

November 09, 2022